Name | Farampator |
Synonyms | CX691 CX 691 CX-691 CX-691 Org2444 ORG2444 Org 24448 ORG 24448 Farampator FARAMPATOR Org24448, CX-691 Methanone, 2,1,3-benzoxadiazol-5-yl-1-piperidinyl- |
CAS | 211735-76-1 |
Molecular Formula | C12H13N3O2 |
Molar Mass | 231.25 |
Storage Condition | Sealed in dry,Store in freezer, under -20°C |
In vivo study | Farampator has potential in treating disorders characterised by cognitive deficits such as Alzheimer's disease and schizophrenia. CX691 attenuates a scopolamine-induced impairment of cued fear conditioning following acute administration (0.1 mg/kg p.o.) and a temporally induced deficit in novel object recognition following both acute (0.1 and 1.0 mg/kg p.o.) and sub-chronic (bi-daily for 7 days) administration (0.01, 0.03, 0.1 mg/kg p.o.). It also improves attentional set-shifting following sub-chronic administration (0.3 mg/kg p.o.). Farampator (500 mg) unequivocally improves short-term memory but appeares to impair episodic memory. Furthermore, it tends to decrease the number of switching errors in the CTMT. Drug-induced side effects (SEs) included headache, somnolence and nausea. Subjects with SEs has significantly higher plasma levels of farampator than subjects without SEs. |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 4.324 ml | 21.622 ml | 43.243 ml |
5 mM | 0.865 ml | 4.324 ml | 8.649 ml |
10 mM | 0.432 ml | 2.162 ml | 4.324 ml |
5 mM | 0.086 ml | 0.432 ml | 0.865 ml |
biological activity | Farampator (CX-691;Org24448) is a positive modulator of the AMPA receptor. |